Zandelisib + Tazemetostat in R/R Follicular Lymphoma

Summary

This research study is being done to estimate the safety and efficacy of zandelisib and tazemetostat in people with relapsed or refractory follicular lymphoma (FL) This research study involves Zandelisib in combination with Tazemetostat. MEI Pharma, Inc, a biotechnology company, is supporting this research study by providing funding for the research study, including the study drug zandelisib.

Timeline

Start

2023-01

Primary completion

2024-12-01

Completion

2026-12-01

Outcome

Outcome not reported

Stopped: “Termination of Zandelisib clinical development globally”

Drugs

Indications